Skip to main content
aTYR PHARMA INC logo

aTYR PHARMA INC — Investor Relations & Filings

Ticker · ATYR ISIN · US0021202025 LEI · 529900ENQUXMC5EBKO36 US Manufacturing
Open in API
Filings indexed 711 across all filing types
Latest filing 2026-06-08 Delisting Announcement
Country US United States of America
Listing US ATYR

About aTYR PHARMA INC

https://www.atyrpharma.com/

aTyr Pharma is a clinical-stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. The company focuses on translating transfer RNA (tRNA) synthetase biology into potential first-in-class therapies. Its primary therapeutic areas of interest are fibrosis and inflammation. aTyr Pharma's lead clinical candidate, efzofitimod (ATYR1923), is being developed for the treatment of pulmonary sarcoidosis and other interstitial lung diseases. The company utilizes its proprietary platform to research the extracellular functionality and signaling pathways of tRNA synthetases to create new product candidates.

Recent filings

Filing Released Lang Actions
8-K
Delisting Announcement Classification · 90% confidence The document is a Form 8-K (Current Report) filed under Item 3.01, titled “Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.” It details Nasdaq’s deficiency notice regarding the sub-$1.00 bid price requirement, an extension period granted by Nasdaq staff, and the potential delisting if compliance is not regained. This is an official Exchange Act notice concerning listing status and potential delisting, which matches the “Delisting Announcement” category (DLST).
2026-06-08 English
8-K
Report Publication Announcement Classification · 92% confidence The document is a Form 8-K (current report) under Item 7.01 disclosing that an investor presentation is being furnished as Exhibit 99.1 and will be placed on the company website. The text itself does not contain substantive presentation content but merely announces the publication and availability of the presentation materials (i.e., “a copy of the presentation materials is attached hereto as Exhibit 99.1”). Per the “menu vs meal” rule, such a brief notice of report release should be classified as a Report Publication Announcement (RPA), not as the report itself.
2026-06-01 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K
Earnings Release Classification · 88% confidence The document is a U.S. SEC Form 8-K current report, specifically Item 2.02 “Results of Operations and Financial Condition,” which furnishes an earnings press release for the quarter ended March 31, 2026. This filing serves to announce the company’s quarterly financial results. Under our taxonomy, initial announcements of quarterly financial results (even when filed as an 8-K) are classified as Earnings Release (ER), not simply a generic regulatory notice. Q1 2026
2026-05-15 English
8-K - aTYR PHARMA INC (0001339970) (Filer)
Regulatory Filings Classification · 85% confidence The document is a United States SEC Form 8-K current report filed by aTyr Pharma, Inc. It provides regulatory disclosures under Items 2.02, 7.01, 8.01 and includes an attached corporate presentation. It is neither a full annual or interim report, nor a simple press release or presentation alone, but a formal SEC regulatory filing. There is no specific category for Form 8-K, so it falls under the fallback "Regulatory Filings" category.
2026-05-11 English
DEFA14A - aTYR PHARMA INC (0001339970) (Filer)
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a company's annual meeting of stockholders. It includes details about the meeting date, proposals to be voted on, board nominees, and instructions for voting. The document is not the proxy statement itself but additional materials related to the proxy solicitation process. The presence of the term 'Definitive Additional Materials' and the content focusing on proxy voting and meeting details aligns with the Remuneration Information category, as proxy statements often include executive compensation information. However, since this document is specifically labeled as DEFA14A and contains proxy solicitation materials, the most appropriate classification is Remuneration Information (DEF 14A).
2026-03-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.